Can Aminoglycosides Be Used as a New Treatment forHelicobacter pylori?In vitroActivity of Recently IsolatedHelicobacter pylori

• DOI: 10.3947/ic.2019.51.1.10
• Publication Date: 2019-04-01T09:03:01Z
• Authors: Kyoung Hwa Lee; Soon Young Park; Su Jin Jeong; Da Hyun Jung; Jie-Hyun Kim; Seok Hoon Jeong; Il-Mo Kang; Young Goo Song
• Keywords: Netilmicin

Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids are expected to supersede the standard therapy for Helicobacter pylori eradication. The aim of this study was confirm whether minimum inhibitory concentration (MIC) aminoglycosides applied remained low against recently isolated H. strains.A total 140 strains were collected period 3 years. Antimicrobial susceptibility tests performed, MICs eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, tobramycin) determined by using Epsilometer test following European Committee on Susceptibility Testing recommendations.The resistance rate clarithromycin high, up 30.7%, although it is major antimicrobial agent used in therapy. MIC₅₀ MIC₉₀ gentamicin (0.25 mg/L 0.75 mg/L) netilmicin (0.19 lower than other alternative therapies In clarithromycin-resistant strains, 0.25 1 gentamicin; values mg/L, respectively.Through use which have pylori, aminoglycoside-intercalated emerge new